Identification of Pharmacological Modulators of HMGB1-Induced Inflammatory Response by Cell-Based Screening
Open Access
- 14 June 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e65994
Abstract
High mobility group box 1 (HMGB1), a highly conserved, ubiquitous protein, is released into the circulation during sterile inflammation (e.g. arthritis, trauma) and circulatory shock. It participates in the pathogenesis of delayed inflammatory responses and organ dysfunction. While several molecules have been identified that modulate the release of HMGB1, less attention has been paid to identify pharmacological inhibitors of the downstream inflammatory processes elicited by HMGB1 (C23-C45 disulfide C106 thiol form). In the current study, a cell-based medium-throughput screening of a 5000+ compound focused library of clinical drugs and drug-like compounds was performed in murine RAW264.7 macrophages, in order to identify modulators of HMGB1-induced tumor-necrosis factor alpha (TNFα) production. Clinically used drugs that suppressed HMGB1-induced TNFα production included glucocorticoids, beta agonists, and the anti-HIV compound indinavir. A re-screen of the NIH clinical compound library identified beta-agonists and various intracellular cAMP enhancers as compounds that potentiate the inhibitory effect of glucocorticoids on HMGB1-induced TNFα production. The molecular pathways involved in this synergistic anti-inflammatory effect are related, at least in part, to inhibition of TNFα mRNA synthesis via a synergistic suppression of ERK/IκB activation. Inhibition of TNFα production by prednisolone+salbutamol pretreatment was also confirmed in vivo in mice subjected to HMGB1 injection; this effect was more pronounced than the effect of either of the agents administered separately. The current study unveils several drug-like modulators of HMGB1-mediated inflammatory responses and offers pharmacological directions for the therapeutic suppression of inflammatory responses in HMGB1-dependent diseases.Keywords
This publication has 31 references indexed in Scilit:
- Cell-Based Screening Identifies Paroxetine as an Inhibitor of Diabetic Endothelial DysfunctionDiabetes, 2013
- Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine releaseJournal of Experimental Medicine, 2012
- HMGB1 Is a Therapeutic Target for Sterile Inflammation and InfectionAnnual Review of Immunology, 2011
- High Mobility Group Box 1 Release from Hepatocytes during Ischemia and Reperfusion Injury Is Mediated by Decreased Histone Deacetylase ActivityJournal of Biological Chemistry, 2010
- A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine releaseProceedings of the National Academy of Sciences, 2010
- NOVEL HMGB1-INHIBITING THERAPEUTIC AGENTS FOR EXPERIMENTAL SEPSISShock, 2009
- Alpha7 cholinergic‐agonist prevents systemic inflammation and improves survival during resuscitationJournal of Cellular and Molecular Medicine, 2009
- CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune ResponsesScience, 2009
- Lidocaine down-regulates nuclear factor-κB signalling and inhibits cytokine production and T cell proliferationClinical and Experimental Immunology, 2008
- Activation of Poly(ADP)-ribose Polymerase (PARP-1) Induces Release of the Pro-inflammatory Mediator HMGB1 from the NucleusJournal of Biological Chemistry, 2007